Last reviewed · How we verify
NCT06954662
Comparison of Whey Protein and Amino Acid Supplementation on Amino Acid and Levodopa Concentrations in People With Parkinson's Disease
EARLY_PHASE1 trial testing Amino acid supplement in Parkinson Disease, Idiopathic in 15 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2025
Quick facts
| Lead sponsor | UConn Health |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 15 |
| Start date | 22 May 2025 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Amino acid supplement — full drug profile →
- Whey Protein Supplement
- Isonitrogenous Placebo Supplement
Conditions studied
- Parkinson Disease, Idiopathic — all drugs for Parkinson Disease, Idiopathic →
Sponsor
UConn Health — full company profile →
Who can join
55 and older, any sex, with Parkinson Disease, Idiopathic. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Circulating levodopa
Time frame: study session 2 (Week 2), 3 (Week 3), and 4 (Week 4). Each session will last approximately 3-4 hours.
Circulating levodopa will be measured from the 10 blood samples at each of the three study visits. -
Circulating amino acids concentrations
Time frame: Session 2 (Week 2), Session 3 (Week 3), Session 4 (Week 4)
High performance liquid chromatography will be used to assess amino acid concentrations in blood samples (10) from each intervention session
Sponsor's own description
The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication in people living with Parkinson disease. The main question it aims to answer is: • Does an amino acid supplement that is specifically made for people with Parkinson disease have short-term improvements in nutrition deficiencies, while minimally interfering with Parkinson disease medication? Researchers will compare the short-term effects of this specialized nutrition supplement to a supplement that is available for everyone to purchase in a store (whey protein supplement-a milk by-product) and to an inactive supplement. Researchers will then check for the indicators of nutrition levels and the presence of dopamine medication in the blood. Researchers will also assess mood and movement abilities in participants. Participants will be asked to: * attend 4 study visits over the course of 4 weeks (initial orientation visit plus 3 intervention visits). * drink one of the 3 supplements (supplements will be mixed into water to create a beverage) at each of the 3 intervention visits. * participate in blood drawings and mood and movement assessments at each of the intervention visits. * engage in a phone call after each intervention visit to determine any delayed responses.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06954662
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease, Idiopathic
Currently open trials in the same condition.
- NCT06859528 — Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease · NA · recruiting
- NCT06609681 — Parkinson Disease: A Model of National Digital Interventions to Prevent or Slow a Rise of Non-Communicable · active not recruiting
Other UConn Health trials
Trials by the same sponsor.
- NCT06115252 — Partnering to Enhance Emerging Adults' Response to Programs · NA · recruiting
- NCT04598074 — Opioid Package Prototype (OPP) · NA · not yet recruiting
- NCT06846853 — Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging) · Phase 4 · recruiting
- NCT06731764 — Novel Approaches to the Treatment of Hypothyroidism · Phase 2, PHASE3 · recruiting
- NCT06668194 — Effect of Force Magnitude on Canine Retraction and Gingival Crevicular Fluid Proteome · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06954662 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UConn Health
- Last refreshed: 9 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06954662.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing